ReviewNature reviews. Cancer2011
Assessing the risk of second malignancies after modern radiotherapy.
Review in Nature reviews. Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 1 synthesis or guideline pooled it.
- In Vitro Models of Cell Senescence: A Systematic Review on Musculoskeletal Tissues and Cells.International journal of molecular sciences · 2023Pooled it
- Individualized Dose-volume Reconstruction Workflow for the Normal Tissues of Pediatric Patients Treated with Passive Scattering Proton Therapy.Radiation research · 2026Article
- Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity.Endocrine reviews · 2025Review
- Review
- From survival of irradiated mice to modern molecular insights: a seventy-year journey in radiobiology at the institute of biophysics, Czech academy of sciences.European biophysics journal : EBJ · 2025Review
- Dose-volume histogram-based comparison of conventional and hypofractionated radiotherapy: lifetime attributable risk estimation in Indian breast carcinoma patients.Radiological physics and technology · 2025Article
- Article
- Article
- Out-of-field neutron radiation from clinical proton, helium, carbon, and oxygen ion beams.Medical physics · 2025Article
- Management of Acquired Hypothalamic Obesity After Childhood-Onset Craniopharyngioma-A Narrative Review.Biomedicines · 2025Review
- From essential basic understanding to clinical application - biological, physical and pathophysiological principles of (low-dose) radiotherapy in benign diseases.Frontiers in immunology · 2025Review
- Unique brain injury patterns after proton vs photon radiotherapy for WHO grade 2-3 gliomas.The oncologist · 2024Article
- Secondary neutron dosimetry for conformal FLASH proton therapy.Medical physics · 2024Article
- Article
- High-LET charged particles: radiobiology and application for new approaches in radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Review
- Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy.Current treatment options in oncology · 2023Review
- Risk and prognosis of secondary esophagus cancer after radiotherapy for breast cancer.Scientific reports · 2023Article
- The intercellular communications mediating radiation-induced bystander effects and their relevance to environmental, occupational, and therapeutic exposures.International journal of radiation biology · 2023Review
- Critical Evaluation of Secondary Cancer Risk After Breast Radiation Therapy with Hybrid Radiotherapy Techniques.Breast cancer (Dove Medical Press) · 2023Article
- Cell Type-Specific Patterns in the Accumulation of DNA Damage Following Multifractional Radiation Exposure.International journal of molecular sciences · 2022Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recent advances in radiotherapy have enabled the use of different types of particles, such as protons and heavy ions, as well as refinements to the treatment of tumours with standard sources (photons). However, the risk of second cancers arising in long-term survivors continues to be a problem. The long-term risks from treatments such as particle therapy have not yet been determined and are unlikely to become apparent for many years. Therefore, there is a need to develop risk assessments based on our current knowledge of radiation-induced carcinogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.